Quantbot Technologies LP Purchases New Stake in Charles River Laboratories International, Inc. $CRL

Quantbot Technologies LP bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 9,215 shares of the medical research company’s stock, valued at approximately $1,442,000.

Several other large investors have also recently added to or reduced their stakes in CRL. Neo Ivy Capital Management acquired a new position in shares of Charles River Laboratories International in the 2nd quarter valued at about $29,000. Rothschild Investment LLC increased its position in Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 84 shares during the period. Atlantic Union Bankshares Corp acquired a new position in shares of Charles River Laboratories International during the third quarter valued at $31,000. Geneos Wealth Management Inc. increased its stake in Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after buying an additional 145 shares during the period. Finally, Allworth Financial LP raised its holdings in Charles River Laboratories International by 172.7% during the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock worth $45,000 after purchasing an additional 190 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

CRL has been the topic of several research reports. Mizuho dropped their price target on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research report on Friday, February 20th. Morgan Stanley set a $185.00 target price on Charles River Laboratories International in a research report on Monday, December 1st. Weiss Ratings restated a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, January 21st. Bank of America upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price on the stock in a research note on Monday, December 15th. Finally, Robert W. Baird set a $193.00 price target on shares of Charles River Laboratories International in a research note on Thursday, February 19th. Ten investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $203.57.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $181.54 on Friday. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $228.88. The firm has a market capitalization of $8.94 billion, a price-to-earnings ratio of -61.33, a P/E/G ratio of 3.07 and a beta of 1.64. The company’s fifty day moving average is $195.88 and its two-hundred day moving average is $180.60. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, beating the consensus estimate of $2.33 by $0.06. The firm had revenue of $994.23 million during the quarter, compared to analysts’ expectations of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The company’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.